KALA BIO, Inc. — Director's Dealing 2022

May 26, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2022-05-26

Reporting Person: RA CAPITAL MANAGEMENT, L.P. (10% Owner)
Reporting Person: RA Capital Healthcare Fund LP (10% Owner)
Reporting Person: Kolchinsky Peter (10% Owner)
Reporting Person: Shah Rajeev M. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-26	Common Stock	S	1005686	$0.3636	Disposed	7039613	Indirect

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $0.35 to $0.3875; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

F2: These securities include 7,039,613 shares held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.